HCPCS Code J2997: Alteplase billing, coverage, and reimbursement

Key Takeaways

HCPCS Code J2997 is the Level II drug code for injection, alteplase recombinant, billed per 1 mg administered

J2997 is covered under Medicare Part B and reimbursed at ASP + 6% in the non-facility setting; rates change quarterly

NDC reporting is required on every J2997 claim submitted to Medicare, using the 5-4-2 format with the N4 qualifier

Practice management software like Pabau helps IV therapy and hospital outpatient billers track drug units, modifiers, and NDC fields to reduce J2997 denials

HCPCS Code J2997 covers injection, alteplase recombinant, per 1 mg, and it sits in the J-series of HCPCS Level II codes maintained by the Centers for Medicare and Medicaid Services (CMS). Getting the units, modifiers, and diagnosis codes right on every claim matters.

This guide covers everything billers and coders need to submit accurate IV therapy EMR software-supported claims for J2997, including Medicare coverage, reimbursement methodology, step-by-step billing instructions, required modifiers, and the most common denial triggers.

J2997 code description and drug details

HCPCS Code J2997 describes alteplase recombinant, a tissue plasminogen activator (tPA) used to dissolve blood clots in acute clinical emergencies. The billing unit is per 1 mg, which means the number of units reported on the claim must equal the exact milligrams administered to the patient.

J2997 quick reference table

Alteplase is a high-alert medication. According to the AAPC’s HCPCS code reference, J2997 falls under the J0000-J8999 injectable drug range. Coders must verify the current CMS HCPCS Level II annual file to confirm any descriptor or coverage changes, because HCPCS codes are updated each January.

Clinical indications and covered diagnoses

Alteplase is FDA-approved for three primary indications: acute ischemic stroke, acute myocardial infarction (AMI), and pulmonary embolism (PE). Medicare covers J2997 when the administered drug is medically necessary and the supporting diagnosis code maps to a covered indication. Facilities that also provide IV vitamin therapy alongside thrombolytics should document the clinical indication explicitly before submitting a claim.

Many AMI patients return afterward for secondary-prevention counseling, where practices track adherence to a low cholesterol diet plan alongside their cardiology follow-up.

Beyond these three approved indications, catheter occlusion clearance is not an off-label use. Cathflo Activase, a 2 mg alteplase formulation, carries its own FDA approval for restoring function to central venous access devices blocked by a clot, separate from the three indications above for full-dose Activase.

Billers should still confirm the applicable Local Coverage Determination (LCD) from their Medicare Administrative Contractor (MAC) before billing, since Cathflo claims follow different coding and coverage rules than full-dose thrombolysis claims. True off-label uses of alteplase, such as deep vein thrombosis thrombolysis, may not be covered under standard Medicare policy and should be verified the same way.

These ICD-10-CM codes link the clinical necessity of alteplase administration to the HCPCS Code J2997 claim line. The diagnosis code on the claim must match the documented indication in the patient’s record. Mismatched or unsupported diagnosis codes are among the top denial triggers for this code.

Billers managing mobile IV therapy operations that occasionally administer thrombolytics should ensure their documentation workflow captures the exact indication before claim submission, cross-referencing G0180 when the same visit is billed under a home health benefit.

Medicare coverage and reimbursement for HCPCS Code J2997

HCPCS Code J2997 is a covered Medicare Part B benefit when medically necessary. The reimbursement methodology follows the Average Sales Price (ASP) model, with payment set at ASP + 6% for non-facility settings. In hospital outpatient settings, the code is bundled under the Hospital Outpatient Prospective Payment System (OPPS) and paid at the applicable Ambulatory Payment Classification (APC) rate.

ASP-based payment amounts change every quarter. The current allowable rate for J2997 must be verified against the CMS ASP Pricing Files or the quarterly ASP drug pricing file published by CMS. Never treat a previously calculated rate as permanent. Using an outdated rate for billing purposes can result in underpayment or compliance flags on post-payment audits.

Reviewing EHR integration for billing is also worthwhile here: practices that integrate their EHR with billing software can automatically pull the current ASP quarter and flag unit discrepancies before claims leave the practice.

Coverage setting differences

Prior authorization is generally not required for Medicare fee-for-service claims for J2997, given the acute emergency nature of its indications. However, commercial payer PA requirements vary significantly, including for infusion suites run on longevity clinic software that bill high-cost injectables under similar rules. Always verify PA status with the individual payer before administration in non-emergency contexts.

Reduce claim denials on high-cost drug codes

Pabau's claims management software helps billing teams track drug units, attach the right modifiers, and validate NDC fields before claims leave the practice. See how it works for injection billing.

Book a demo

How to bill J2997: step-by-step

Submitting HCPCS Code J2997 accurately requires attention to four claim elements: units, NDC, modifiers, and diagnosis linkage. Miss any one and the claim denies. Here is the submission sequence for a standard Medicare Part B claim using the CMS-1500 form.

1. Determine units administered. Count the exact milligrams of alteplase administered. Each 1 mg = 1 unit on the claim. A patient receiving 50 mg requires 50 units billed on the J2997 line.
2. Record the National Drug Code (NDC). Identify the NDC from the product label or vial. Format: 5-4-2 with leading zeros preserved. Add qualifier N4 before the NDC in the appropriate claim field (Box 24 on CMS-1500 or the equivalent electronic 837P segment).
3. Attach the correct modifier(s). Append modifier JA for intravenous administration (most common for alteplase). If drug from a single-dose vial is discarded, append modifier JW on a separate line to report the wasted amount.
4. Link the supporting ICD-10-CM diagnosis code. Use the diagnosis pointer in Box 24E to connect the J2997 line to the applicable condition code (e.g. I63.x for ischemic stroke).
5. Report the place of service (POS) code. Use POS 11 for physician office. Hospital outpatient claims go through the UB-04 form with POS 22.
6. Verify against the current ASP quarter. Cross-check the expected reimbursement against the current CMS ASP pricing file before submission. Flag any line where calculated reimbursement falls outside expected range.

Practices using dedicated claims management software can automate steps 3, 4, and 6 through built-in modifier rules and real-time fee schedule integration. Facilities managing IV therapy billing workflows benefit from software that validates NDC format before a claim reaches the clearinghouse.

Required modifiers for J2997

Verify all modifier requirements against your MAC’s current LCD and applicable CMS transmittals. Modifier JZ, introduced in 2023, made wastage reporting mandatory for single-dose vials even when no drug is discarded, so billers must choose between JW and JZ on every applicable J2997 claim line.

Common billing errors and denial reasons for J2997

Most J2997 denials trace back to five preventable errors. Understanding them before submission is far cheaper than working a denial after the fact.

• Incorrect unit count: billing 1 unit for a 50 mg dose is the single most common J2997 error. Units must equal the milligrams administered, not the number of vials opened.
• Missing or malformatted NDC: Medicare requires the NDC on every drug claim. A missing N4 qualifier or truncated NDC (missing leading zeros) triggers an automatic denial. Use digital clinical forms that prompt staff to record the NDC at the point of administration.
• Mismatched diagnosis code: the ICD-10-CM code in Box 21 must support the clinical necessity of alteplase. An unspecified cardiovascular code without specificity (e.g. I99.9) will not link adequately to J2997.
• Missing JW/JZ modifier: since 2023, claims from single-dose vials require one of these modifiers. Omitting both results in a claim edit.
• Wrong place of service: billing with POS 11 when the administration occurred in a hospital outpatient department (POS 22) routes the claim to the wrong payment system and causes rejection.

Billers should also review HIPAA compliance in billing workflows when storing alteplase administration records electronically, particularly for facilities that digitise vial lot numbers and administration timestamps alongside claim data.

J2997 vs related thrombolytic drug codes

Alteplase is not the only thrombolytic billed with a J-code. The table below maps the key thrombolytic HCPCS codes so billers can confirm they are using the right one before submitting a claim.

Using J3101 (tenecteplase) when alteplase was administered, or vice versa, results in a payment mismatch and a likely audit flag. These are distinct drugs with different ASP rates and different FDA-approved indications. Always cross-reference the product label with the HCPCS code descriptor before billing.

Documentation requirements for J2997 claims

Every J2997 claim submitted to Medicare requires supporting documentation that can withstand a post-payment audit or Additional Documentation Request (ADR). Incomplete records are the root cause of most recovered overpayments on drug claims, which is why many emergency departments standardize capture with an emergency medical form built around the same physician order and dosing fields.

• Physician order: a signed order specifying the drug, dose, route of administration, and clinical indication
• Administration record: nursing or clinical note documenting the actual mg administered, time, and route
• NDC information: vial lot number, NDC, and expiration date from the product label or pharmacy record
• Diagnosis linkage: the patient record must clearly support the ICD-10-CM code(s) reported on the claim
• Wastage documentation: if modifier JW is used, the record must show the number of mg discarded from the vial
• Prior authorization (commercial payers): for non-Medicare claims, include the PA number in the appropriate claim field

Practices using EMR for IV therapy that includes structured drug administration logs catch missing documentation before it reaches a claim. When the administration record, NDC capture, and diagnosis linkage are part of the same clinical workflow rather than separate manual steps, audit exposure shrinks.

Pair this with prescription management software to keep medication records audit-ready and timestamped at the point of care.

For practices still building their documentation templates, a new client intake form can be adapted to capture the pre-treatment clinical details that support J2997 medical necessity documentation. Use the PGM Billing HCPCS lookup to cross-check the current J2997 descriptor and verify no descriptor revisions have been issued since your last billing update.

Conclusion

Most J2997 claim failures come from the same small set of errors: wrong unit count, missing NDC, mismatched diagnosis, and omitted JW/JZ modifier. Getting these right on the first submission protects revenue and keeps alteplase claims off the audit radar.

Pabau’s claims management software helps billing teams build pre-submission checklists directly into their drug-billing workflow, so J2997 and similar high-value injection codes are validated before they reach the clearinghouse. To see how it works for your practice, book a demo.

Continue your research

Need a documentation template for IV drug administration? new client intake form covers the essential fields for capturing clinical necessity before administration.

Need the billing guide for the IV push itself? 96374 covers the push administration technique used for many alteplase doses.

Billing a home health visit around the same infusion? G0180 covers the physician certification that often accompanies home-administered thrombolytic claims.

Frequently Asked Questions